All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What are the current challenges in ALL that need to be addressed?
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Selina M. Luger, University of Pennsylvania, Philadelphia, US. We asked: What are the current challenges in ALL that need to be addressed?
What are the current challenges in ALL that need to be addressed?
Here, she highlights a number of considerations regarding ALL treatment strategies:
1) Should all patients receive transplant for the treatment of ALL?
2) Do all patients with Philadelphia chromosome-positive ALL require intensive chemotherapy?
3) Are there patients with Philadelphia chromosome-negative ALL who demonstrate good responses without chemotherapy?
4) Should targeted agents be incorporated into chemotherapy regimens?
Selina M. Luger concludes by highlighting the lack of targeted agents available for T-cell ALL and outlines emerging therapeutics in this setting.
More about...
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox